Forty-Sixth Board Meeting

<p>Gabriella Fesus from the European Commission, Belgium, Italy, Portugal, Spain Constituency is designated as Rapporteur for the 46th Board Meeting.</p>

<p>The Agenda for the 46th Board Meeting (GF/B46/01_Rev1) is approved.</p>

<p>Based on the recommendation of the Strategy Committee, as presented in GF/B46/03_rev1, the Board:</p> <ol> <li>approves the Strategy Narrative for the 2023-2028 Global Fund Strategy in Annex 1 to GF/B46/03_rev1 and requests that the Secretariat develop, for presentation to the Strategy Committee in March 2022 and subsequently the Board in May 2022, an approach for Strategy implementation with a focus on delivering the key changes outlined in the Strategy using all existing levers and identifying where new solutions will be required; and</li> <li>expresses its recognition to the Standing Committees for their work in the context of the development of the Strategy and looks forward to the continuous engagement between the Board, Secretariat and the Standing Committees, in line with their respective mandates, throughout the implementation of the Strategy.</li> </ol>

<p>Based on its review of the Secretariat’s analysis and recommendations on the global disease split for the 2023-2025 allocation period, and the Strategy Committee’s related deliberations, the Board:</p> <ol> <li>Acknowledges that the total amount of funds available for country allocation (including approved sources of funds for country allocation and any additional funds approved as available for country allocation) will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishments results from the 7th Replenishment;</li> <li>Approves that the apportionment of available country allocation funds across disease components (“Global Disease Split”) for the 2023-2025 allocation period will be determined by the total amount of available funds for country allocation for the 2023-2025 allocation period approved by the Board;</li> <li>Acknowledging the increased share of deaths from tuberculosis among the three diseases, approves the following Global Disease Split for the 2023-2025 allocation period, which increases funding for tuberculosis while preserving funding and potential for scale-up for HIV and malaria: <ol type="a"> <li>Any available funds for country allocation up to and including US$ 12 billion will be apportioned as follows: 50% for HIV/AIDS, 18% for tuberculosis, and 32% for malaria; and</li> <li>Any additional available funds for country allocation above US$ 12 billion will be apportioned as follows: <ol type="i"> <li>i. 45% of such funds will be apportioned to HIV/AIDS;</li> <li>ii. 25% of such funds will be apportioned to tuberculosis; and</li> <li>iii. 30% of such funds will be apportioned to malaria.</li> </ol> </li> </ol> </li> <li>Recognizing the need to further increase funding for tuberculosis and maximize the quality and impact of tuberculosis programs in line with the ambition of the Global Fund Strategy Narrative, requests the Secretariat, partners and committees, as relevant, to propose and implement specific options to address these needs, including: <ol type="a"> <li>Presenting to the Board, at its 47th meeting, a proposal to leverage catalytic investments for the 2023-2025 allocation period to mobilize additional resources to reduce deaths from tuberculosis;</li> <li>Aggressively exploring, on an ongoing basis, evidence-based portfolio optimization and prioritization opportunities in order to more effectively address tuberculosis incidence and mortality in high burden countries;</li> <li>Continuing to pursue and monitor domestic co-financing commitments required to increase overall financing for tuberculosis; and</li> <li>Continuing to pursue innovative finance opportunities to increase funding to tuberculosis in high burden countries.</li> </ol> </li> <li>Requests the Global Fund’s Independent Evaluation Function to commission, in consultation with the Strategy Committee, technical partners and Secretariat, an external evaluation of the Global Fund’s approach to resource allocation to maximize impact, to inform evidence-based decision making on these issues ahead of the 8th replenishment, and to support more effective delivery of the Global Fund Strategy.</li> </ol>

<ol> <li>The Board: <ol type="a"> <li>recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;</li> <li>affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/SC17/14_Rev2 and pursuant to decision point GF/SC17/DP02;</li> <li>further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/AFC17/02_Rev2 and pursuant to decision point GF/AFC17/DP02; and</li> <li>instructs the Secretariat to provide greater reporting on emerging risk trends and the effectiveness and results of the assurance measures, including the additional assurances put in place.</li> </ol> </li> <li>Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statements, including risk appetites, target risk levels and timeframes to achieve target risk, as set forth in Annex 1 to GF/B46/06, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date.</li> <li>This decision point and the amended Risk Appetite Statements approved by it shall supersede decision point GF/B39/DP11 (May 2018).</li> </ol>

<p>The Board notes the recommendation of the Strategy Committee and of the Ethics and Governance Committee, as set forth in GF/B46/05 rev1, with respect to the new independent evaluation model which shall replace the Technical Evaluation Reference Group ("TERG") and decides to approve the creation of the Independent Evaluation Panel, as described in GF/B46/05 rev1.</p> <p>Accordingly, the Board:</p> <ol> <li>Amends the Global Fund Bylaws, as set forth in Annex 1 of GF/B46/05 rev1, effective 31 December 2022;</li> <li>Amends the Charter of the Strategy Committee, as set forth in Annex 2 of GF/B46/05 rev1, effective 31 December 2022;</li> <li>Approves the Terms of Reference of the Independent Evaluation Panel ("IEP"), as set forth in Annex 3 of GF/B46/05 rev1 effective 31 December 2022, which will constitute one structure of the independent evaluation function previously held by the TERG, noting that approval of subsequent non-material modifications to this document are delegated to the Strategy Committee;</li> <li>Requests the Secretariat, under the oversight of the relevant standing Committees, to update any policies, relevant governance documents, charters, terms of reference, agreements or prior decisions needed to align with the documents approved under paragraphs 1, 2 and 3 of this decision point and to manage the orderly transition between the Technical Evaluation Reference Group ("TERG") and the IEP;</li> <li>Requests the Strategy Committee, in fulfilling its oversight role over the independent evaluation function, to consider the effectiveness of the guidance and procedures developed to safeguard both the independence and the learning components of the evaluation function; and</li> <li>Decides to dissolve TERG following the transition period ending 31 December 2022 and instructs the Strategy Committee to develop and oversee transitional arrangement between the IEP and the TERG.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the:</p> <ol> <li>2022 Work Plan and Budget Narrative, as set forth in GF/B46/02; and</li> <li>2022 Operating Expenses Budget in the amount of US$ 322.2million, as set forth in GF/B46/02 (the “2022 OPEX Budget”), which includes (i) US$ 65.5 million for in-country and external assurance activities, as described in GF/B46/02, and (ii) US$ 14.9 million for the Office of the Inspector General’s 2022 operating expenses.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the protracted public health crisis in Venezuela, which has been further exacerbated by the COVID-19 pandemic, and continues to adversely impact the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Notes that while the Board exceptionally approved the eligibility of Venezuela’s malaria component under GF/B41/EDP06, resulting in an allocation of US$ 19,800,000 for the 2020-2022 allocation period, Venezuela’s HIV and tuberculosis components were not eligible to receive allocations in the 2020-2022 allocation period;</li> <li>Acknowledges the new proposal for exceptional funding in 2022 and 2023 presented by the Secretariat and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B46/ERXX and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B46/ERXX and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B46/ERXX and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 12,000,000, for the years 2022 and 2023, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020), as well as increases to C19RM awards previously approved by the Board that either exceed USD 10 million or include interventions not previously approved by the Board;</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER03; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>Based on the rationale provided in GF/B46/ER06, the Board: <ol type="a"> <li>Approves that any additional 6th Replenishment pledges received through 30 September 2022 will be used to support the COVID-19 Response Mechanism (C19RM);</li> <li>Approves that any additional C19RM funds may be awarded through 31 March 2023;</li> <li>Approves to revise the thresholds for Board approval of C19RM awards set out in paragraph 5.d of GF/B44/EDP18 based on the total additional C19RM funding made available, as follows: <ol type="i"> <li>If up to US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 45 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 15 million, where such increases scale-up interventions approved by the Board;</li> <li>If more than US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 55 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 20 million, where such increases scale-up interventions approved by the Board; and</li> <li>Threshold amounts will continue to be measured in aggregate by country, not including any amounts awarded under the fast-track approach or C19RM funds awarded in 2020;</li> </ol> </li> <li>Agrees that all other parameters of C19RM under GF/B44/EDP18 remain unchanged; and</li> <li>Approves that the Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 December 2023.</li> </ol> </li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER07; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>Based on the recommendation of the Strategy Committee, the Board approves the revision for Key Performance Indicator 6e as presented in GF/B46/ER08.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B46/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the Report of the Global Fund 46th Board Meeting, as set forth in GF/B46/22.</p>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER10; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER11 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER11 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B46/ER11 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<ol> <li>The Board approves the renewal for one additional term of: <ol type="i"> <li>Robert Samels as Independent Member of the Audit and Finance Committee with financial audit expertise;</li> <li>Diana Isiye as Independent Member of the Audit and Finance Committee with forensic investigation expertise; and</li> <li>Mohammad Ali Mubarak Kisubi as Independent Member of the Ethics and Governance Committee with ethics expertise.</li> </ol> </li> <li>The individuals appointed under this decision point will begin their term on 12 May 2022 and serve for two years or until appointment of their respective successors.</li> <li>The Board notes each independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> </ol>

<p>The Board expresses its concerns around the devastating effects of the recent invasion of Ukraine; Tropical Cyclone Ana in Mozambique and Malawi; and the conflict in Ethiopia’s northwestern Tigray region and the grave consequences for human lives in these areas. The Board further reaffirms its commitment to responding efficiently and quickly to emergency contexts to ensure the continuity of life-saving health services through Global Fund-supported programs. Therefore, the Board:</p> <ol> <li>Acknowledges that additional funding is required for the Emergency Fund in order to ensure that there is sufficient funding to respond to current and evolving emergency needs;</li> <li>Approves the reallocation of USD 30 million from Audit and Finance Committee-approved portfolio optimization funds to the Emergency Fund.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$45 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER14; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2021 Annual Financial Report, including the 2021 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B46/ER15.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2021 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B46/ER15.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, aslisted in Table 1 of GF/B46/ER21 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposedPrincipal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by theSecretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shallbe committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for eachcountry disease component among its constituent grants, provided that the Technical Review Panel (the“TRP”) validates any redistribution that constitutes a material change from the program and fundingrequest initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B46/ER22 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount thatmay be available for the relevant implementation period of each country disease component’s constituentgrants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for eachcountry disease component among its constituent grants, provided that the Technical Review Panel (the“TRP”) validates any redistribution that constitutes a material change from the program and fundingrequest initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed inTable 3 of GF/B46/ER23 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee, as set forth in GF/AFC18/DP03, the Board authorizes the appointment of KPMG SA as the Global Fund’s external auditor for a term to cover financial years 2022-2028 to align with the next Global Fund Strategy cycle (2023-2028).</p>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend tothe Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awardsexceeding US$45 million, as measured in aggregate by country (not including anyfunding awarded for COVID-19 commodities through fast-track investments orC19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 ofGF/B46/ER18; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling offunding available for each country among its constituent grants in accordance with thepreviously approved principles under GF/B44/EDP18.</li> </ol>

<ol> <li>The Board approves the appointment of:<br /> <ol type="i"> <li>Edward Ouko as Chair of the Audit and Finance Committee:</li> <li>Sylvie Chantereau as Vice-Chair of the Audit and Finance Committee:</li> <li>Paul Schaper as Chair of the Ethics and Governance Committee</li> <li>Julia Martin as Chair of the Strategy Committee</li> <li>Carolyn Gomes as Vice-Chair of the Strategy Committee</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Revanta Dharmarajah, Developed Country NGOs</li> <li>Andriy Klepikov, Developing Country NGOs</li> <li>Sara Osman, Eastern Mediterranean Region</li> <li>Birgitte Hagelund, European Commission, Belgium, Italy, Portugal and Spain</li> <li>Hiroshi Matsumura, Japan</li> <li>Andreas Karlberg Pettersen, Point Seven</li> <li>Greg Ferrante, Private Foundations</li> <li>Erika Satterwhite, Private Sector</li> <li>Rai Mahimapat Ray, South East Asia</li> <li>Michael Ruffner, the United States of America</li> <li>Daniel Domelevo, West and Central Africa</li> <li>Jiayan Huang, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Aisha Al Kuwari, Additional Public Donors</li> <li>Alexandru Chitic Patapievici, the World Bank</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:<br /> <ol type="i"> <li>Erika Castellanos, Communities</li> <li>Edellin Calixte Randriamiandrisoa, Eastern and Southern Africa</li> <li>Miŝo Pejkovic, Eastern Europe and Central Asia</li> <li>Mohamed Chakroun, Eastern Mediterranean Region</li> <li>Sarah Burwood, France</li> <li>Annette Chammas, Germany</li> <li>Roisin Fegan, the United Kingdom</li> <li>Anthony (Jin) Park, the United States of America</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Timothy Poletti, Canada, Switzerland and Australia</li> <li>Javier Hourcade Bellocq, Communities</li> <li>Gerald Gwinji, Eastern and Southern Africa</li> <li>Tonka Varleva, Eastern Europe and Central Asia</li> <li>Stéphanie Seydoux, France</li> <li>Birgit Pickel, Germany</li> <li>Hampus Holmer, Point Seven</li> <li>Sherwin Charles, Private Sector</li> <li>Sarah Boulton, the United Kingdom</li> <li>Massimo Ghidinelli, Latin America and the Caribbean</li> <li>Djalo Boukou Oumar Mele, West and Central Africa</li> <li>Jim Tulloch, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Melanie Renshaw, Partners</li> <li>Victor Bampoe, UNAIDS</li> <li>Mubashar Sheikh, World Health Organization</li> </ol> </li> <li>The Board notes that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group (to be succeeded by the Independent Evaluation Panel pursuant to Board decision GF/B46/DP06) also serve as non-voting members of the Strategy Committee.</li> <li>The Board further notes that each of the individuals named in this decision will commence their term on 13 May 2022 and will serve for two years or until appointment of their successor.</li> </ol>